BR112021022225A2 - Composto, pró-droga e composição farmacêutica - Google Patents
Composto, pró-droga e composição farmacêuticaInfo
- Publication number
- BR112021022225A2 BR112021022225A2 BR112021022225A BR112021022225A BR112021022225A2 BR 112021022225 A2 BR112021022225 A2 BR 112021022225A2 BR 112021022225 A BR112021022225 A BR 112021022225A BR 112021022225 A BR112021022225 A BR 112021022225A BR 112021022225 A2 BR112021022225 A2 BR 112021022225A2
- Authority
- BR
- Brazil
- Prior art keywords
- compound
- prodrug
- pharmaceutical composition
- cancer
- compounds
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 4
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 3
- 239000000651 prodrug Substances 0.000 title abstract 3
- 229940002612 prodrug Drugs 0.000 title abstract 3
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Saccharide Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
composto, pró-droga e composição farmacêutica. a presente invenção se refere a um composto com a seguinte fórmula (i): bem como as pró-drogas correspondentes, composições farmacêuticas compreendendo os referidos compostos, em particular para o tratamento do câncer.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP19305574 | 2019-05-06 | ||
PCT/EP2020/062617 WO2020225323A1 (en) | 2019-05-06 | 2020-05-06 | New therapeutic vectors and prodrugs for treating cancers |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112021022225A2 true BR112021022225A2 (pt) | 2021-12-28 |
Family
ID=66625887
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112021022225A BR112021022225A2 (pt) | 2019-05-06 | 2020-05-06 | Composto, pró-droga e composição farmacêutica |
Country Status (8)
Country | Link |
---|---|
US (1) | US20220227741A1 (pt) |
EP (1) | EP3965893A1 (pt) |
JP (1) | JP2022531612A (pt) |
CN (1) | CN114173877A (pt) |
AU (1) | AU2020268749A1 (pt) |
BR (1) | BR112021022225A2 (pt) |
CA (1) | CA3139378A1 (pt) |
WO (1) | WO2020225323A1 (pt) |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
HUE027549T2 (hu) | 2002-07-31 | 2016-10-28 | Seattle Genetics Inc | Hatóanyagot tartalmazó konjugátumok és alkalmazásuk rák, autoimmun betegség vagy fertõzéses betegség kezelésére |
FR3017298B1 (fr) * | 2014-02-07 | 2016-03-04 | Centre Nat Rech Scient | Conjugues et pro-drogues pour le traitement du cancer et de maladies inflammatoires |
BR112017006602A2 (pt) | 2014-10-01 | 2017-12-19 | Medimmune Llc | método de conjugação de um polipeptídeo |
WO2018210824A1 (en) * | 2017-05-16 | 2018-11-22 | Universite De Strasbourg | Protein-drug conjugates and their use in the treatment of cancers |
WO2019081455A1 (en) * | 2017-10-23 | 2019-05-02 | Mablink Bioscience | LIGAND-MEDICINAL CONJUGATE COMPRISING A UNIQUE MOLECULAR WEIGHT POLYSARCOSIN |
-
2020
- 2020-05-06 AU AU2020268749A patent/AU2020268749A1/en active Pending
- 2020-05-06 BR BR112021022225A patent/BR112021022225A2/pt unknown
- 2020-05-06 JP JP2021566112A patent/JP2022531612A/ja active Pending
- 2020-05-06 US US17/595,012 patent/US20220227741A1/en active Pending
- 2020-05-06 WO PCT/EP2020/062617 patent/WO2020225323A1/en unknown
- 2020-05-06 CA CA3139378A patent/CA3139378A1/en active Pending
- 2020-05-06 CN CN202080034028.0A patent/CN114173877A/zh active Pending
- 2020-05-06 EP EP20722369.4A patent/EP3965893A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
US20220227741A1 (en) | 2022-07-21 |
EP3965893A1 (en) | 2022-03-16 |
CN114173877A (zh) | 2022-03-11 |
JP2022531612A (ja) | 2022-07-07 |
WO2020225323A1 (en) | 2020-11-12 |
CA3139378A1 (en) | 2020-11-12 |
AU2020268749A1 (en) | 2021-12-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112018007381A2 (pt) | compostos úteis como imunomoduladores | |
DOP2018000257A (es) | Piridinas sustituidas con heteroarilo y métodos de uso | |
BR112014018959A8 (pt) | Compostos, composições farmacêuticas, utilizações de um composto e métodos para o tratamento do câncer | |
BR112018003026A2 (pt) | composições compreendendo um inibidor de pi3k e um inibidor de hdac | |
CO6480975A2 (es) | Mimetico de smac | |
UY35242A (es) | Inhibidores de fosfatidilinositol 3-quinasa | |
BR112017003658A2 (pt) | composto, mistura, métodos para tratamento de uma doença e para inibição de uma glicosidase, e, composição farmacêutica. | |
CO2018000589A2 (es) | Oxiesteroles y composiciones farmacéuticas que los contienen | |
CU20110052A7 (es) | Compuestos orgánicos | |
DOP2014000012A (es) | Nuevos compuestos de 4-piperidinilo para uso como inhibidores de la tankirasa | |
BR112013021537A2 (pt) | derivados de tiazolilpenil-benzenosulfonamido como inibidores da quinase | |
BR112016006651B8 (pt) | compostos derivados de quinolizina substituídos, composição farmacêutica que os compreende e uso dos referidos compostos | |
BR112015008037A2 (pt) | compostos, processo para a preparação de um composto, composição farmacêutica, utilização do composto, método para o tratamento do câncer e invenção | |
UY36702A (es) | Piridinas sustituidas y métodos de uso | |
ECSP10010271A (es) | Derivados de tiazol usados como inhibidores de pi 3-cinasa | |
BR112016028845A2 (pt) | composto, composição farmacêutica e uso de um composto | |
BR112017018305A2 (pt) | desacetoxitubulisina h e análogos da mesma | |
ECSP13012494A (es) | Inhibidores de oxadiazol de la producción de leucotrieno. | |
BR112015008717A2 (pt) | composto, composição farmacêutica, método de tratar diabetes do tipo ii, uso do composto de fórmula (i), medicação para o tratamento de diabetes do tipo ii | |
BRPI0906444B8 (pt) | compostos de 4-piridinona, composição farmacêutica que os compreende, bem como uso dos mesmos | |
BR112017022158A2 (pt) | compostos, composições farmacêuticas e uso de um composto | |
MX2022000945A (es) | Composicion para incrementar la expresion de pgc-1alfa. | |
BR112021006229A2 (pt) | composto, composição farmacêutica, e, método para tratamento de um câncer | |
BR112022012130A2 (pt) | Compostos antelmínticos compreendendo uma estrutura azaindólica | |
BRPI1008855B8 (pt) | derivados de indol, seu uso como agentes anticâncer, seu processo para preparação e composição farmacêutica que os compreende |